AI주식인사이트AI Stock Insight
B

HLB제넥스

187420KOSDAQ기초 의약물질 제조업

55.5 / 100

Reference Date: 2026-04-13

Financial Score23.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 4.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

HLB제넥스 is a biotech company founded in 2000, specializing in the development and production of customized enzymes and bio-healthcare materials using core technologies like microbial display and recombinant protein secretion. Its main business areas include industrial specialty enzymes, bio-healthcare materials, and microbiome-enzyme products, with key offerings such as eco-friendly catalase, lactase for GOS production, and nattokinase for cardiovascular health. The company is also advancing its pipeline drug GF103, an oral treatment for wet age-related macular degeneration, currently preparing for Phase I clinical trials.

Number of Employees

82people

Average Salary

57.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
3.50Industry Average 33.458.0Point

Half of industry avg (excellent)

PBR
1.46Industry Average 2.035.5Point

Lower than industry avg (good)

ROE
55.20Industry Average -4.293.5Point

Well below industry avg

Debt Ratio
33.29Industry Average 6.610.0Point

5.0x industry avg (risky)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲26.8% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲122.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -4.4% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 2,715Won52-week high 3,63052-week low 2,350
1-month return4.0Point

1m +4.42% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0
  • Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-04-06
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-02
  • Neutral주식등의대량보유상황보고서(일반)2026-04-01
  • Neutral정기주주총회결과2026-03-30
  • Neutral기업설명회(IR)개최2026-03-25